ECCO 2022
Combined endpoints as new therapy goals
high5immunology.tv | IBD | ECCO 2022
SELECTION, GALAXI 1, LUCENT-1
ECCO 2022
Combined endpoints as new therapy goals
VEGA
ECCO 2022
Combination trials open a new door in IBD treatment
SPARE
ECCO 2022
Is the continuation of combination therapy the key to…
SERENITY
ECCO 2022
The potential of histology in Crohn´s disease and how…
EARNEST, DIVERGENCE 2
ECCO 2022
Light at the end of the Pouchitis track
RESTORE-UC
ECCO 2022
Microbiota manipulation: Still a lot to learn
SPARE
ECCO 2022
Is stopping of therapy an option in CD?
NOR-DRUM B
ECCO 2022
Proactive TDM or SOC for monitoring infliximab…
ECCO 2022
The interleukin-17 conundrum
NOR-DRUM B
ECCO 2022
Proactive TDM
RESTORE-UC
ECCO 2022
A negative control trial for FMT in UC
VEGA
ECCO 2022
The first combination therapy trial
SPARE
ECCO 2022
SPARE study in ECCO 2022
SEAVUE / STARDUST
ECCO 2022
Ustekinumab for fistulizing disease
ECCO 2022
Is the speedity of the steroid tapering important…
SPARE
ECCO 2022
How to deescalate treatment in CD?
VEGA
ECCO 2022
Combination of biologics
RESTORE-UC
ECCO 2022
FMT is not a promising option for UC patients
VEGA
ECCO 2022
Combination of biologics - finally arrived in IBD!?
VEGA
ECCO 2022
Combination with different classes of drugs in moderate…
SPARE
ECCO 2022
Infliximab withdrawl leeds to a higher risk of…
SPARE
ECCO 2022
Withdrawal of infliximab or anti-metabolite therapy in…
VEGA
ECCO 2022
Will we improve the management of IBD by combining…
DIVERGENCE 2
ECCO 2022
Filgotinib for fistulizing disease
NOR-DRUM B
ECCO 2022
A new opportunity for proactive TDM disease control
RESTORE-UC
ECCO 2022
FMT in UC - still far away from the success story
SPARE
ECCO 2022
When to withdraw therapy in crohn's disease?
SPARE
ECCO 2022
Ist der Therapiestopp eine Option in CD?
SPARE
ECCO 2022
Wann Beendigung von Infliximab oder Immunmodulatoren…
ECCO 2022
Das Interleukin-17 Rätsel
VEGA
ECCO 2022
Il primo trial di terapia biologica di combinazione
ECCO 2022
Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την…
VEGA
ECCO 2022
Combinazione di biologici
VEGA
ECCO 2022
Kombination von Biologika - endlich bei IBD…
VEGA
ECCO 2022
Allons nous améliorer la prise en charge des MICI en…
NOR-DRUM B
ECCO 2022
Una nuova opportunità per i TDM nel controllo proattivo…
SPARE
ECCO 2022
מחקר SPARE ב ECCO 2022
RESTORE-UC
ECCO 2022
FMT ist kein vielversprechender Ansatz für UC-Patienten
SPARE
ECCO 2022
Du nouveau sur l’allégement thérapeutique au cours de…
NOR-DRUM B
ECCO 2022
Προληπτική μέτρηση των θεραπευτικών επιπέδων του…
RESTORE-UC
ECCO 2022
Un essai négatif sur la transplantation de microbiote…
RESTORE-UC
ECCO 2022
FMT w colitis ulcerosa - wciąż daleko od sukcesu
CLARITY IBD
Ecco 2022
COVID-19: still a moving target!
ECCO 2022
Inflammatory bowel disease and cancer risk
OCTAVE / RIVETING, DIVERGENCE 2, U-ACHIEVE
ECCO 2022
Can we translate rheumatoid arthritis to ulcerative…
ECCO 2022
Which IBD patients have a higher risk of safety…
VEGA
ECCO 2022
Is combination therapy safe?
VEGA
ECCO 2022
A touch of the near future in IBD treatment
ECCO 2022
The heart is apparently safe with continuous Ozanimod…
MECONIUM
ECCO 2022
Breastmilk is tuning IBD risk
MECONIUM
ECCO 2022
Muttermilch beeinflusst das IBD-Risiko
ECCO 2022
Il cuore sembra essere apparentemente al sicuro durante…
VEGA
ECCO 2022
Uno sguardo al prossimo futuro nel trattamento delle…
VEGA, GALAXI 1, QUASAR, LUCENT-1
ECCO 2022
The race is on IL-23 – exciting data for CD and UC
EARNEST, VEDOKIDS, VEDOIBD
ECCO 2022
Vedolizumab: promising data for pouchitis and IBD in…
U-ACHIEVE / U-ACCOMPLISH, SELECTION
ECCO 2022
Efficacy update on JAKis
ECCO 2022
Mucosal healing: Will efficacy data translate into real…
SEAVUE / STARDUST, DIVERGENCE 2
ECCO 2022
Fistulizing Crohn‘s disease - new treatment options…
GALAXI 1
ECCO 2022
Guselkumab as maintenace treatment in Crohn's Disease
EARNEST
ECCO 2022
Great news on pouchitis treatment - vedolizumab…
EARNEST
ECCO 2022
New opportunity in pouchitis treatment
EARNEST
ECCO 2022
Vedolizumab is effective in chronic pouchitis after…
QUASAR, GALAXI 1, LUCENT-1, FORTIFY
ECCO 2022
Selective IL-23 blockade
ECCO 2022
Upadacitinib - will it be the game changer in UC?
ECCO 2022
New ways of treatment
EARNEST
ECCO 2022
Vedolizumab in chronic pouchitis - a new chapter in…
U-ACHIEVE / U-ACCOMPLISH, SELECTION / SELECTIONLTE, DIVERGENCE 2, OCTAVE / RIVETING
ECCO 2022
JAK inhibition
QUASAR, GALAXI 1, LUCENT-1, FORTIFY
ECCO 2022
Anti-IL-23 - a turning point?
QUASAR, GALAXI 1, LUCENT-1, FORTIFY
ECCO 2022
Anti-IL-23 - eine Zeitenwende?
ECCO 2022
Upadacitinib - nowy lek, duże nadzieje
QUASAR, GALAXI 1, LUCENT-1, FORTIFY
ECCO 2022
Selektive IL-23 Blockade
EARNEST
ECCO 2022
Una nuova opportunità nel trattamemto della pouchite
ECCO 2022
Nuevos caminos en el tratamiento
U-ACHIEVE / U-ACCOMPLISH, SELECTION / SELECTIONLTE, DIVERGENCE 2, OCTAVE / RIVETING
ECCO 2022
JAK-Inhibition
GALAXI 1
ECCO 2022
Guselkumab come terapia di mantenimento
EARNEST
ECCO 2022
Wedolizumab w pouchitis - początek nowego rozdziału w…
SELECTION
ECCO 2022
Disease control is possible!
LUCENT-1 and others
ECCO 2022
New therapy goals: urgency and disease clearance
SELECTION
ECCO 2022
New therapeutic goals in UC
U-ACHIEVE
ECCO 2022
Patient relevant outcomes also show efficacy of…
EPIMAD registry
ECCO 2022
Natural history of anal ulcerations in pediatric-onset…
SERENITY
ECCO 2022
Histological findings in mirikizumab treatment
ECCO 2022
New goals for IBD
SELECTION
ECCO 2022
Disease Control ist möglich!
ECCO 2022
Nuevas objetivos en las EII
EPIMAD registry
ECCO 2022
Histoire naturelle de la maladie de Crohn ano-périnéale…
LUCENT-1 and others
ECCO 2022
Urgency und Disease Clearance
VIP, CLARITY IBD
ECCO 2022
The efficacy of COVID-19 vaccines in IBD - what's new?
VIP, RECOVERI
ECCO 2022
COVID-19 in patients with IBD stratified acc. to…
VIP, CLARITY IBD
ECCO 2022
Skuteczność szczepień przeciw COVID-19 w IBD - nowe…
VIP, RECOVERI
ECCO 2022
תגובה חיסונית לחיסונים כנגד קורונה בחולים עם מחלות מעי…
ECCO 2022
Point of Care Testing / AI / Telemedicine
TRUST BEYOND
ECCO 2022
Ultrasound as a predictor of treatment response
TRUST BEYOND
ECCO 2022
Ultraschall als Prädiktor des Therapieansprechens
ECCO 2022
Digitale Tools, KI und Telemedizin
EITOS, VERSUS-CD, DUMBO
ECCO 2022
Spanish women leading contribution to ECCO 2022
ECCO 2022
ECCO guidelines on pregnancy
EITOS, VERSUS-CD, DUMBO
ECCO 2022
Las mujeres lideran la contribución española a la ECCO…
ECCO 2022
ECCO Richtlijnen zwangerschap
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!